Researchers discovered a unique case in a Colombian family where a woman with a genetic predisposition for Alzheimer’s remained cognitively healthy due to a rare APOE gene mutation, the Christchurch mutation. This mutation disrupts the typical progression of Alzheimer’s, suggesting new prevention strategies.
Breaking link between early, late stages of disease may prevent dementia.
Alzheimer’sAlzheimer's disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer's disease, but there are medications that can help ease the symptoms.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]” tabindex=”0″ role=”link”>Alzheimer’s disease has plagued one large Colombian family for generations, striking down half of its members in the prime of life. But one member of that family evaded what had seemed would be fate: Despite inheriting the genetic defect that caused her relatives to develop dementia in their 40s, she stayed cognitively healthy into her 70s.
Study Reveals Protective Gene Mutation
Researchers at Washington University School of Medicine in St. Louis now think they know why. A previous study had reported that, unlike her relatives, the woman carried two copies of a rare variant of the APOE gene known as the Christchurch mutation.
In this study, researchers used genetically modified mice to show that the Christchurch mutation severs the link between the early phase of Alzheimer’s disease, when a protein called amyloid beta builds up in the brain, and the late phase, when another protein called tau accumulates and cognitive decline sets in. So the woman stayed mentally sharp for decades, even as her brain filled with massive amounts of amyloid. The findings, published on December 11 in the journal Cell, suggest a new approach to preventing Alzheimer’s dementia.
Insights from Senior Author David M. Holtzman, MD
“Any protective factor is very interesting, because it gives us new clues to how the disease works,” said senior author David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology.
“As people get older, many begin to develop some amyloid accumulation in their brains. Initially, they remain cognitively normal. However, after many years the amyloid deposition begins to lead to the accumulation of the tau protein. When this happens, cognitive impairment soon ensues. If we can find a way to mimic the effects of the APOE Christchurch mutation, we may be able to stop people who already are on the path to Alzheimer’s dementia from continuing down that path.”
Understanding Alzheimer’s Disease Progression
Alzheimer’s develops over the course of about 30 years. The first two decades or so are silent; amyloid slowly accumulates in the brain without causing ill effects. When amyloid levels reach a tipping point, however, they kick off phase two, which involves multiple interrelated destructive processes: A protein called tau forms tangles that spread through the brain; brain metabolism slows down, and the brain begins to shrink; and people start to experience memory and thinking problems. The disease follows the same pattern in people with genetic and nongenetic forms of Alzheimer’s.
The Colombian Family’s Genetic Mutation
The Colombian families carry a mutation in a gene called presenilin-1 that causes their brains to develop far too much amyloid buildup beginning in their 20s. People who carry the mutation accumulate amyloid so quickly that they reach the tipping point and start showing signs of cognitive decline in middle age. One rare exception is a woman who had more amyloid in her brain in her 70s than her relatives did in their 40s, but only very minimal signs of brain injury and cognitive impairment.
“One of the biggest unanswered questions in the Alzheimer’s field is why amyloid accumulation leads to tau pathology,” Holtzman said. “This woman was very, very unusual in that she had amyloid pathology but not much tau pathology and only very mild cognitive symptoms that came on late. This suggested to us that she might hold clues to this link between amyloid and tau.”
Further Research and Findings
A 2019 study revealed that, along with a mutation in presenilin-1, the woman also carried the Christchurch mutation in both copies of her APOE gene, another gene associated with Alzheimer’s disease. But with only one person in the world known to have this particular combination of genetic mutations, there was not enough data to prove that the Christchurch mutation was responsible for her remarkable resistance to Alzheimer’s and not simply a coincidental finding.
To solve this puzzle, Holtzman and first author Yun Chen, a graduate student, turned to genetically modified mice. They took mice genetically predisposed to overproduce amyloid and modified them to carry the human APOE gene with the Christchurch mutation. Then, they injected a tiny bit of human tau into the mouse brains. Normally, introducing tau into brains already brimming with amyloid seeds a pathological process in which tau collects into aggregates at the site of injection, followed by the spread of such aggregates to other parts of the brain.
Not so in the mice with the Christchurch mutation. Much like the Colombian woman, the mice developed minor tau pathology despite extensive amyloid plaques. The researchers discovered that the key difference was the activity levels of microglia, the brain’s waste-disposal cells. Microglia tend to cluster around amyloid plaques. In mice with the APOE Christchurch mutation, the microglia surrounding amyloid plaques were revved up and hyperefficient at consuming and disposing of tau aggregates.
Conclusion and Potential Therapeutic Implications
“These microglia are taking up the tau and degrading it before tau pathology can spread effectively to the next cell,” Holtzman said. “That blocked much of the downstream process; without tau pathology, you don’t get neurodegeneration, atrophy, and cognitive problems. If we can mimic the effect that the mutation is having, we may be able to render amyloid accumulation harmless, or at least much less harmful, and protect people from developing cognitive impairments.”
Reference: “APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread” by Yun Chen, Sihui Song, Samira Parhizkar, Jennifer Lord, Yiyang Zhu, Michael R. Strickland, Chanung Wang, Jiyu Park, G. Travis Tabor, Hong Jiang, Kevin Li, Albert A. Davis, Carla M. Yuede, Marco Colonna, Jason D. Ulrich and David M. Holtzman, 11 December 2023, Cell.
DOI: 10.1016/j.cell.2023.11.029
Funding: JPB Foundation, Cure Alzheimer’s Fund, NIH/National Institutes of HealthThe National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. Founded in 1887, it is a part of the U.S. Department of Health and Human Services. The NIH conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program. With 27 different institutes and centers under its umbrella, the NIH covers a broad spectrum of health-related research, including specific diseases, population health, clinical research, and fundamental biological processes. Its mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]” tabindex=”0″ role=”link”>National Institutes of Health, Alzheimer’s Association
Source: SciTechDaily
